Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Kidney/drug effects/physiopathology"'
Autor:
Gilles Mentha, Emiliano Giostra, Laurent Spahr, Isabelle Morard, Jérôme Dumortier, Pietro Majno, Antoine Hadengue, Philippe Morel
Publikováno v:
Liver Transplantation, Vol. 13, No 5 (2007) pp. 658-64
Sirolimus (SRL) has been proposed to replace calcineurin inhibitors (CNI) in case of CNI-induced toxicity. The aim of this study was to evaluate the efficacy and safety of conversion from CNI to SRL in maintenance liver transplantation (LT) patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298bdd13dfc4e02000b655418ca19ae8
https://doi.org/10.1002/lt.21116
https://doi.org/10.1002/lt.21116
Autor:
Pappas Christos, Andreas Fotopoulos, Georgios N. Kalambokis, Michalis Economou, Epameinondas V. Tsianos, Papadimitriou Konstantinos, Kosta Paraskevi, Afroditi Katsaraki, Jihad Al Bokharhii
Publikováno v:
Digestive Diseases and Sciences. 50:1771-1777
Increased endogenous nitric oxide production has been proposed as an important mediator of the peripheral arterial vasodilation and the hyperdynamic circulation in cirrhosis, whereas a decreased intrahepatic production of nitric oxide has been implic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d7852138d4015d9f74afefe05b6ffe
https://doi.org/10.1007/s10620-005-2935-8
https://doi.org/10.1007/s10620-005-2935-8
Autor:
Jim, Young, Juliane, Schäfer, Christoph A, Fux, Hansjakob, Furrer, Enos, Bernasconi, Pietro, Vernazza, Alexandra, Calmy, Matthias, Cavassini, Rainer, Weber, Manuel, Battegay, Heiner C, Bucher, S, Yerly
Publikováno v:
AIDS, Vol. 26, No 5 (2012) pp. 567-75
Background: Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89773cafd0a6a8e5115793d5ddc0d632
https://pubmed.ncbi.nlm.nih.gov/22398568
https://pubmed.ncbi.nlm.nih.gov/22398568
Autor:
Kalaitzidis, R. G., Elisaf, M. S.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality not only amongst the general population, but also in patients with chronic kidney disease (CKD). Persons with CKD are much more likely to die of CVD than to experience kidne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::12e12d003e7a2150e6c809bc6df0accf
http://olympias.lib.uoi.gr/jspui/handle/123456789/22787
http://olympias.lib.uoi.gr/jspui/handle/123456789/22787
A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis. In the herein presented "letter to the editor", the administration of tadalafil did not influence port
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::3b1fa261c6c9f8efce4824c87c5da4ce
http://olympias.lib.uoi.gr/jspui/handle/123456789/21312
http://olympias.lib.uoi.gr/jspui/handle/123456789/21312
Hypertension is one of the major risk factors for cardiovascular disease. Angiotensin receptor blockers (ARBs) are a class of antihypertensive drugs with established efficacy and favorable safety profile. Telmisartan, a member of the ARB family, hold
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::e418175d32bf91422d9c2670260b1f36
http://olympias.lib.uoi.gr/jspui/handle/123456789/23724
http://olympias.lib.uoi.gr/jspui/handle/123456789/23724
Autor:
Heiner C. Bucher, Milos Opravil, Pietro Vernazza, Hansjakob Furrer, Luigia Elzi, Matthias Cavassini, Bernard Hirschel, Enos Bernasconi, Christoph A Fux, Marcel Wolbers, Mathew Simcock
Publikováno v:
Antiviral Therapy, Vol. 12, No 8 (2007) pp. 1165-1173
BackgroundA growing number of case reports have described tenofovir (TDF)-related proximal renal tubulopathy and impaired calculated glomerular filtration rates (cGFR). We assessed TDF-associated changes in cGFR in a large observational HIV cohort.Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff0182146948a01ee448b91f03aff09
https://archive-ouverte.unige.ch/unige:7244
https://archive-ouverte.unige.ch/unige:7244
Large-scale trials established that statin administration in hypercholesterolaemic individuals and patients with coronary heart disease (CHD) significantly reduces the risk of vascular events and death. This benefit was primarily attributed to their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::e3572974ee812775c9a77fa0276ab87a
http://olympias.lib.uoi.gr/jspui/handle/123456789/22278
http://olympias.lib.uoi.gr/jspui/handle/123456789/22278
Autor:
HIRAKAWA, Toharu
Publikováno v:
泌尿器科紀要. 15(1):22-41
Split renal function studies were carried out on thirty-two urologic patients with emphasis on the changes of renal functions under hexamethonium (C6) loading. For such a purpose, PAHclearance, STS-clearance, urinary out-put, specific gravity, pH, so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::9ab4c403d091f99fa0ff0f79165675cc
http://hdl.handle.net/2433/119962
http://hdl.handle.net/2433/119962
Autor:
Daskalopoulos, G., Giacomo Laffi, Morgan, T., Pinzani, M., Harley, H., Reynolds, T., Zipser, R. D.
Publikováno v:
Scopus-Elsevier
Furosemide occasionally causes azotemia in patients with ascites, independently of induced volume depletion. To define this effect, we measured renal clearances in patients with chronic liver disease and ascites and in nonascitic controls. Furosemide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::557fdf00fc8842127456f3662b417ab3
http://olympias.lib.uoi.gr/jspui/handle/123456789/21016
http://olympias.lib.uoi.gr/jspui/handle/123456789/21016